| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |